Gene-guided identifications of a structure-chimeric cyclotide viphi I from Viola philippica: potential functions against cadmium and nematodes.

Chimeric cyclotide viphi I Functions against cadmium and nematodes Recombinant preparations Viola philippica

Journal

Plant science : an international journal of experimental plant biology
ISSN: 1873-2259
Titre abrégé: Plant Sci
Pays: Ireland
ID NLM: 9882015

Informations de publication

Date de publication:
08 Jul 2024
Historique:
received: 20 02 2024
revised: 04 07 2024
accepted: 06 07 2024
medline: 11 7 2024
pubmed: 11 7 2024
entrez: 10 7 2024
Statut: aheadofprint

Résumé

The cyclic peptides, cyclotides, are identified mostly with 29~31-aa (amino acid residues) but rarely with ≥ 34-aa in plants. Viola philippica is a well-known medicinal plant but a rare metallophyte with cyclotides. A hypothesis was hence raised that the potential novel 34-aa cyclotide of Viola philippica would clearly broaden the structural and functional diversities of plant cyclotides. After homology-cloning the cyclotide precursor gene of VpCP5, a 34-aa cyclotide (viphi I) was identified to be larger than 22 other known cyclotides in V. philippica. It had a chimeric primary structure, due to its unusual loop structures (8 residues in loop 2 and 6 residues in loop 5) and aa composition (3 E and 5R), by using phylogenetic analyses and an in-house cyclotide analysis tool, CyExcel_V1. A plasmid pCYC-viphi_I and a lab-used recombinant process were specially constructed for preparing viphi I. Typically, 0.12 or 0.25mgml

Identifiants

pubmed: 38986912
pii: S0168-9452(24)00212-7
doi: 10.1016/j.plantsci.2024.112185
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112185

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflict of interests The authors declare that they have no conflict of interest.

Auteurs

Xiaojie Zhang (X)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: zhangxiaojie9205@163.com.

Ruohong Chen (R)

Sun Yat-sen University, School of Life Sciences, Guangzhou, 510275, China. Electronic address: 5624915@qq.com.

Haoyue Shu (H)

Sun Yat-sen University, School of Life Sciences, Guangzhou, 510275, China. Electronic address: 185906958@qq.com.

Peihui Liang (P)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: 262820089@qq.com.

Ting Qin (T)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: 1253449752@qq.com.

Kemei Wang (K)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: 2445460537@qq.com.

Aimin Guo (A)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: 1794475872@qq.com.

David J Craik (DJ)

The University of Queensland, Institute for Molecular Bioscience, Brisbane, 4072 QLD Australia. Electronic address: d.craik@imb.uq.edu.au.

Bin Liao (B)

Sun Yat-sen University, School of Life Sciences, Guangzhou, 510275, China. Electronic address: lsslb@sysu.edu.cn.

Jun Zhang (J)

Guangdong Pharmaceutical University, School of Life Sciences and Biopharmaceutics, Guangzhou, 510006, China. Electronic address: lsszhangj@gdpu.edu.cn.

Classifications MeSH